Increase in Prevalence of HPV Infections Drive Global CIN and HR-HPV Treatment Market
According to our new research study on "CIN and HR-HPV Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Disease Type, Strain Type, Offering, Product Type, and End User,” the CIN and HR-HPV Treatment Market was valued at US$ 11,635.17 million in 2022 and is projected to reach US$ 17,164.61 million by 2028; it is estimated to grow at a CAGR of 6.7% from 2023 to 2028. An increase in the prevalence of human papillomavirus (HPV) infections and favorable initiatives for preventing cervical cancer are the major factors contributing to the CIN and HR-HPV Treatment Market growth.
Increase in Prevalence of HPV Infections Favors CIN and HR-HPV Treatment Market Growth
Cervical intraepithelial neoplasia (CIN), also called cervical dysplasia, is characterized by the formation of proliferative lesions with abnormal cell growth on the surface of the cervix. These lesions replace a part of or the entire cervical squamous epithelium, and they are perceived as precursors of cervical cancer. Cervical dysplasia is caused by HPV infection. Over 200 variants of HPV are known to cause infections among humans, and ~40 of these variants affect genitals upon spreading through sexual contact. 12 of these HPV types are associated with a high risk of cancer, and ~10 are associated with low-risk cancer. ~70% of cervical cancer cases are caused by HPV type 16 and type 18, which are HR-HPV serotypes. According to the American Cancer Society, 9 out of 10 cervical cancers are caused by HPV; in 2023, ~13,960 women in the US are likely to be diagnosed with cervical cancer, and the disease is expected to cause death among ~4,310 women. According to a study published in the National Library of Medicine, in 2022, most cervical cancer cases were caused by HPV 16, accounting for 55-60% of cervical cancer cases reported worldwide in that year. HPV 18 accounts for 10-15% of cervical cancer cases in the world. A persistent HPV infection can result in CIN among subjects that are immunocompromised and infected with HIV, and have a history of smoking.
According to the Centers for Disease Control and Prevention (CDC), cervical cancer due to HPV infection is the ninth most common cancer among women in the US, and each year, ~13 million people are infected with HPV infection. According to the HPV Information Center, US, in 2023, ~3.9% of women are likely to be infected with cervical HPV16 or 18, and 71.2% of cervical cancers are attributed to HPVs 16 or 18. According to the European Cancer Organization, in 2020, HPV infections were the cause of ~2.5% of cancer cases in Europe, and the prevalence of high-risk HPV infection exceeds 15% among the European population. According to the World Health Organization, ~66,000 women were diagnosed with cervical cancer in the WHO European region in 2022. According to a study published in the National Library of Medicine, in 2020, sub-Saharan Africa had the world’s highest cervical cancer rates, which can be largely attributed to the low screening rate in the region. Cervical cancer accounts for 20-25% of all cancers among women in sub-Saharan Africa, and its incidence ranges from 30 to 40 per 100,000 women, more than double of that reported among women worldwide. In South Africa, cervical cancer is the leading cause of cancer mortality among women; it is the second most common type of cancer among women from the age group of 15-44. According to the same source, ~62.8% of invasive cervical cancer cases in South Africa are caused by HPV 16 or 18. In 21 of the 48 sub-Saharan African countries, cervical cancer ranks among the most common causes of death among women, and almost 100% of all cases of cervical cancer are associated with the high prevalence of HPV.
Thus, a rise in the prevalence of HPV infections contributes to the growth of the CIN & HR-HPV treatment market.
Future Trends
Use of Modern Technologies in CIN & HR-HPV Screening and Diagnosis to Lead to New Trends in CIN & hrHPV Market
Health authorities across the world recommend routine cervical cancer screenings to women as ~30% of the grade 3 CIN lesions develop into invasive cancers within 30 years. Slow progression provides several opportunities for detection and treatment. The manual cervical cancer screening methods are not always accurate, which results in skips in the detection of some lesions. Ongoing improvements in screening techniques are likely to increase cervical cancer detection rates and decrease mortality rates.
According to the Pan American Health Organization, in 2021, the World Health Organization released new recommendations to guide research into AI-based screening technologies. With this, researchers working on projects related to HPV diagnoses and therapies are likely to introduce more effective cervical cancer screening modalities in the future, thereby ensuring the early detection of precancer cases. Persistent HR-HPV infection can lead to cervical cancer; thus, the timely diagnosis of HPV infection and screening of high-risk populations can assist in preventing cervical cancer. The genotyping of HPV will simplify the process of risk assessment in women with positive cervical smear results and HPV DNA-positive results, which would aid in the better screening and management of cervical cancer. An article published in the National Library of Medicine in 2020 describes the Artificial Intelligence Monitoring for HPV (AIM-HPV) approach that integrates high-tech and low-tech solutions for DNA-based and point-of-care cancer screening. Such effective automated cytological detection models based on AI are likely to help guide the triage of cervical cells and help detect CIN more effectively than standard pathological biopsy techniques in the future.
In 2021, the WHO Collaborating Centre for Cervical Cancer Elimination partnered with the University of Miami's Sylvester Comprehensive Cancer Centre, which will serve as a hub for research and technical assistance to help countries eliminate cervical cancer. Thus, such technological advancements are likely to bring new trends in the CIN & HR-HPV market in the coming years.
Fujirebio Europe NV, Qiagen NV, Zilico Ltd, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd, INOVIO Pharmaceuticals Inc, Bioneer Corp, Antiva Biosciences Inc, and Thermo Fisher Scientific Inc are among the leading companies operating in the CIN & hrHPV market.
Based on offering, the CIN and HR-HPV Treatment Market is segmented into cervical intraepithelial neoplasia 1, cervical intraepithelial neoplasia 2, and cervical intraepithelial neoplasia 3. The cervical intraepithelial neoplasia 3 segment held the largest market share in 2022, and it is anticipated to register the highest CAGR during the forecast period. Based on strain type, the CIN and HR-HPV Treatment Market is segmented into HPV 16, HPV 18, and others. The HPV 18 segment held the largest share of the market in 2022, and the same segment is expected to register the highest CAGR during the forecast period. By offering, the CIN and HR-HPV Treatment Market is bifurcated into diagnostic method and treatment. By product type, the market is segmented into kits & reagents, instruments, and services. By end user, the CIN and HR-HPV Treatment Market is segmented as hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. By geography, the CIN and HR-HPV Treatment Market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
In terms of revenue, North America dominated the CIN and HR-HPV Treatment Market growth accounting highest market share. On the other hand, Asia Pacific accounts for highest CAGR for CIN and HR-HPV Treatment Market during the forecast period.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com